Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC

NCT04895930 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Non-Small-Cell Lung Cancer

Interventions

DRUG: Furmonertinib
DRUG: Anlotinib

Sponsor

Shanghai Chest Hospital

Collaborators

[object Object]